Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Miguel Martín, Alfonso López de et al.|Breast Cancer Research and Treatment|2024Cited by 21
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Yolanda Ruano et al.|European Journal of Cancer|2025Cited by 10
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabRodrigo Sánchez-Bayona, Aleix Prat, Olga Martínez‐Sáez et al.|npj Breast Cancer|2025Cited by 6
Abstract P5-13-24: Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancerRodrigo Sánchez-Bayona, Pablo Tolosa, Santiago Terán et al.|Cancer Research|2022Cited by 4
Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancerSantiago Terán, Rodrigo Sánchez-Bayona, Manuel Alva et al.|The Breast|2023Cited by 4